論文 - 詳細
| RRC ID | 56151 |
|---|---|
| 著者 | Nakatake R, Kaibori M, Nakamura Y, Tanaka Y, Matushima H, Okumura T, Murakami T, Ino Y, Todo T, Kon M. |
| タイトル | Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. |
| ジャーナル | Cancer Sci |
| Abstract |
Multimodality therapies are used to manage patients with hepatocellular carcinoma (HCC), although advanced HCC is incurable. Oncolytic virus therapy is probably the next major breakthrough in cancer treatment. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 kills tumor cells without damaging the surrounding normal tissues. Here we investigated the antitumor effects of T-01 on HCC and the host's immune response to HCC cells. The cytopathic activities of T-01 were tested in 14 human and 1 murine hepatoma cell line in vitro. In various mouse xenograft models, HuH-7, KYN-2, PLC/PRF/5 and HepG2 human cells and Hepa1-6 murine cells were used to investigate the in vivo efficacy of T-01. T-01 was cytotoxic to 13 cell lines (in vitro). In mouse xenograft models of subcutaneous, orthotopic and peritoneal tumor metastasis in athymic mice (BALB/c nu/nu), the growth of tumors formed by the human HCC cell lines and hepatoblastoma cell line was inhibited by T-01 compared with that of mock-inoculated tumors. In a bilateral Hepa1-6 subcutaneous tumor model in C57BL/6 mice, the growth of tumors inoculated with T-01 was inhibited, as was the case for contralateral tumors. T-01 also significantly reduced tumor growth. T-01 infection significantly enhanced antitumor efficacy via T cell-mediated immune responses. Results demonstrate that a third-generation oncolytic HSV-1 may serve as a novel treatment for patients with HCC. |
| 巻・号 | 109(3) |
| ページ | 600-610 |
| 公開日 | 2018-3-1 |
| DOI | 10.1111/cas.13492 |
| PMID | 29288515 |
| PMC | PMC5834814 |
| MeSH | Animals Carcinoma, Hepatocellular / immunology Carcinoma, Hepatocellular / therapy* Hep G2 Cells Herpesvirus 1, Human / physiology* Humans Liver Neoplasms / immunology Liver Neoplasms / therapy* Mice Mice, Inbred BALB C Mice, Inbred C57BL Oncolytic Viruses / physiology* Peritoneal Neoplasms / immunology Peritoneal Neoplasms / secondary Peritoneal Neoplasms / therapy* Treatment Outcome Virus Replication Xenograft Model Antitumor Assays |
| IF | 4.751 |
| 引用数 | 6 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | Vero(RCB0001) Hep G2 |